BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/22/2026

6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Get Alerts BMRN Hot Sheet

Price: $55.90 +2.21%

EPS Growth %: -34.0%

Financial Fact:
Provision for income taxes: -24.02M

Today's EPS Names:
OCCI, MAYS, CRMT, More

Join SI Premium – FREE

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $279.9 million versus the consensus estimate of $289.44 million.

Updated 2016 Financial Guidance

Revenue Guidance ($ in millions)

Item
	Provided August 4, 2016	Updated October 27, 2016
Total BioMarin Revenues	$1,100 to $1,150	Unchanged
Vimizim Net Product Revenues	$340 to $360	Unchanged
Naglazyme Net Product Revenues	$290 to $320	Unchanged
Kuvan Net Product Revenues	$340 to $360	Unchanged

Select Income Statement Guidance ($ in millions, except percentages)

Item
	Provided August 4, 2016	Updated October 27, 2016
Cost of Sales (% of Total BioMarin Revenues)	18.0% to 19.0%	Unchanged
Selling, General and Admin. Expense	$470 to $490	$460 to $480
Research and Development Expense	$670 to $690	$650 to $670
GAAP Net Loss	$(620) to $(650)	$(600) to $(630)
non-GAAP Loss	$(30) to $(50)	$(10) to $(30)

Recent Key Program Updates

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

Create E-mail Alert Related Categories

Earnings, Guidance

Related Entities

Earnings

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!